Portal de Periódicos da CAPES

Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes

2022; Springer Science+Business Media; Volume: 54; Issue: 3 Linguagem: Inglês

10.1007/s11239-022-02701-w

1573-742X

Angelo Silverio, Francesco Paolo Cancro, Marco Di Maio, Michele Bellino, Luca Esposito, Mario Centore, Albino Carrizzo, Paola Di Pietro, Anna Borrelli, Giuseppe De Luca, Carmine Vecchione, Gennaro Galasso,

Antiplatelet Therapy and Cardiovascular Diseases

Abstract Introduction : The aim of this study was to evaluate the association of lipoprotein(a) [Lp(a)] levels with long-term outcome in patients with recent history of myocardial infarction (MI), and to investigate if diabetes may influence this association. Methods : Consecutive MI patients who underwent urgent/emergent coronary angiography from February 2013 to June 2019 were prospectively collected. The primary outcome was the composite of MI recurrence and all-cause death. The propensity score weighting technique was used to account for covariates potentially influencing the relationship between Lp(a) levels and the study outcomes. Results : The study population consisted of 1018 post-MI patients (median age 63 years). Diabetes was reported in 280 patients (27.5%), who showed lower Lp(a) levels than patients without diabetes (p = 0.026). At a median follow-up of 1121 days, the primary outcome was reported in 182 patients (17.9%). At univariable Cox regression analysis, Lp(a) was associated with the risk of the primary outcome in the overall population and in non-diabetic patients, but not in diabetics. The adjusted Cox regression analysis confirmed the independent association between Lp(a) values and the primary outcome in non-diabetic patients, but not in diabetics. Lp(a) levels > 70 mg/dL were independently associated with the risk of the primary outcome in non-diabetic patients (adjusted HR: 2.839; 95% CI, 1.382–5.832), but not in diabetics. Conclusions : In this real-world post-MI population, increasing Lp(a) levels were significantly associated with the risk of recurrent MI and all-cause death, and very high Lp(a) serum concentration independently predicted long-term outcome in non-diabetic patients, but not in diabetics.